Cellectis S.A.

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Real-time Euronext Paris 08:42:50 2024-05-24 am EDT 5-day change 1st Jan Change
2.545 EUR -2.12% Intraday chart for Cellectis S.A. -3.78% -7.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
Cellectis: alliance with AstraZeneca finalized CF
Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca MT
AstraZeneca: equity investment in Cellectis CF
AstraZeneca completes collaboration and investment deal with Cellectis AN
AstraZeneca Secures 44% Stake in French Biotech Cellectis MT
Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC CI
Cellectis CFO Bing Wang Retires, Interim CFO Appointed MT
Cellectis Announces Chief Financial Officer Changes CI
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT
Cellectis S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cellectis S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs CI
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
Chart Cellectis S.A.
More charts
Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ALCLS Stock
  4. News Cellectis S.A.
  5. European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading